FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Kun Li1, 2, 3, *, Qunfeng Guo4, *, Jun Yang4, *, Hui Chen3, Kewen Hu3, Juan Zhao1, 2, Shunxin Zheng1, 2, Xiufeng Pang3, Sufang Zhou1, 2, Yongyan Dang3, Lei Li3 1Department of Biochemistry and Molecular Biology, Guangxi Medical University, Nanning, Guangxi, China 2National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Guangxi Medical University, Nanning, Guangxi, China 3Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai, China 4Department of Orthopedics, Changzheng Hospital, The Second Military Medical University, Shanghai, People’s Republic of China *These authors have contributed equally to this work Correspondence to: Yongyan Dang, email: yydang@bio.ecnu.edu.cn Xiufeng Pang, email: xfpang@bio.ecnu.edu.cn Sufang Zhou, email: zsf200000@163.com Lei Li, email: lllkzj@163.com Keywords: FOXD3, colon cancer, EGFR, Ras/Raf/MEK/ERK signal pathway Received: June 03, 2016 Accepted: November 12, 2016 Published: December 03, 2016